HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

zardaverine

structure given in first source

Also Known As:

6-(4-difluoromethoxy-3-methoxyphenyl)-3(2H)pyridazinone

Networked: 12 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridazines: 11
    - zardaverine: 12

Experts

1.	Allart-Simon, Ingrid: 1 article (06/2022)
2.	Audonnet, Sandra: 1 article (06/2022)
3.	Braux, Julien: 1 article (06/2022)
4.	Gangloff, Sophie C: 1 article (06/2022)
5.	Guillaume, Christine: 1 article (06/2022)
6.	Gérard, Stéphane: 1 article (06/2022)
7.	Moniot, Aurélie: 1 article (06/2022)
8.	Sapi, Janos: 1 article (06/2022)
9.	Siboni, Renaud: 1 article (06/2022)
10.	Tirouvanziam, Rabindra: 1 article (06/2022)

Related Diseases

1.	Inflammation (Inflammations) 06/01/1993 - "In this study we evaluated the effect of zardaverine in an in vivo animal model of airway inflammation and hyperresponsiveness. " 01/01/1991 - "Zardaverine and dexamethasone prevent bronchial eosinophilia and neutrophilia with similar dosage of 30 microM/kg orally, suggesting that this PDE III/IV inhibitor may be useful for both, bronchorelaxation and reduction of inflammation in asthma therapy."
2.	Respiratory Insufficiency (Respiratory Failure) 08/01/2003 - "Zardaverine and aerosolised iloprost in a model of acute respiratory failure." 08/01/2003 - "In this study, the impact of aerosolised prostacyclin (PGI2) and iloprost in the absence or presence of subthreshold intravascular doses of the dual-selective phosphodiesterase-3/4 inhibitor zardaverine was investigated in an experimental model of acute respiratory failure. "
3.	Asthma (Bronchial Asthma) 06/01/1993 - "Zardaverine is a novel phosphodiesterase III/IV inhibitor, developed as a potential therapeutic agent for asthma. " 09/01/1992 - "Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma." 01/01/1991 - "Zardaverine and dexamethasone prevent bronchial eosinophilia and neutrophilia with similar dosage of 30 microM/kg orally, suggesting that this PDE III/IV inhibitor may be useful for both, bronchorelaxation and reduction of inflammation in asthma therapy."
4.	Bronchial Spasm 05/01/1994 - "It has been determined that zardaverine is more than 30 times as potent as theophylline in inhibiting acetylcholine-induced bronchospasms, which is also supported by forced expiratory flow data." 07/01/1994 - "In anesthesized, ventilated guinea pigs, the i.v. ID50S against OA-induced bronchospasm were: rolipram = 0.2 mg/kg, siguazodan > 10 mg/kg and zardaverine = 2.4 mg/kg. When administered at doses up to 7.5 mg/kg, i.v., rolipram or siguazodan were markedly less effective (i.e., < or = 50% inhibition) than zardaverine (ID50S = 2.4 and 1.7 mg/kg, respectively) at blocking exogenous histamine- or LTD4-induced bronchospasm. " 07/01/1994 - "In conscious guinea pigs, zardaverine (5 mg/kg, intragastrically (i.g.) or the combination of rolipram and siguazodan (5 mg/kg each) were substantially more effective than rolipram or siguazodan alone at inhibiting aerosol histamine- or LTD4-induced bronchospasm. " 07/01/1994 - "In guinea pigs sensitized to ovalbumin (OA), the effects of three PDE inhibitors were compared: siguazodan (PDE III selective, IC50 = 0.7 microM), rolipram (PDE IV selective, IC50 = 0.8 microM) and zardaverine (dual PDE III/IV, IC50S = 2.5 microM and 1.1 microM, respectively) against histamine-, leukotriene (LT) D4- and OA-induced bronchospasm in vitro and in vivo. "
5.	Costello Syndrome 01/01/2017 - "Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient."

Related Drugs and Biologics

1.	Phosphoric Diester Hydrolases (Phosphodiesterases)
2.	Iloprost (Ventavis)
3.	Epoprostenol (Prostacyclin)
4.	Type 3 Cyclic Nucleotide Phosphodiesterases
5.	Rolipram
6.	Leukotriene D4
7.	Transforming Growth Factor alpha (TGF-alpha)
8.	Leukotrienes
9.	Valproic Acid (Depakote)
10.	Theophylline (Theon)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)